These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26626782)

  • 1. Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?
    Miller EO; Schwartz RG
    J Nucl Cardiol; 2017 Feb; 24(1):119-121. PubMed ID: 26626782
    [No Abstract]   [Full Text] [Related]  

  • 2. Regadenoson: a focused update.
    Ghimire G; Hage FG; Heo J; Iskandrian AE
    J Nucl Cardiol; 2013 Apr; 20(2):284-8. PubMed ID: 23229649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary apoplexy after regadenoson myocardial perfusion scan.
    Shetty S; Gnanaraj J; Jayamani Roshan S; El Accaoui R
    J Nucl Cardiol; 2020 Feb; 27(1):336-339. PubMed ID: 30168027
    [No Abstract]   [Full Text] [Related]  

  • 4. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Doukky R; Fughhi I; Campagnoli T; Wassouf M; Ali A
    J Nucl Cardiol; 2017 Feb; 24(1):112-118. PubMed ID: 26582040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
    Vij A; Golzar Y; Doukky R
    J Nucl Cardiol; 2018 Feb; 25(1):137-149. PubMed ID: 28653271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.
    Rangel MO; Morales Demori R; Voll ST; Wassouf M; Dick R; Doukky R
    J Nucl Cardiol; 2015 Oct; 22(5):1008-18. PubMed ID: 25500799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
    Palani G; Husain Z; Salinas RC; Karthikeyan V; Karthikeyan AS; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):605-11. PubMed ID: 21541818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
    Amer KA; Hurren JR; Edwin SB; Cohen G
    Pharmacotherapy; 2017 Jun; 37(6):657-661. PubMed ID: 28475259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.
    Doukky R; Rangel MO; Dick R; Wassouf M; Alqaid A; Margeta B
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):1029-37. PubMed ID: 23224354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.
    Kolkailah AA; Iskander M; Iskander F; Patel PP; Khan R; Doukky R
    J Nucl Cardiol; 2022 Feb; 29(1):101-110. PubMed ID: 32632913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
    Doukky R; Morales Demori R; Jain S; Kiriakos R; Mwansa V; Calvin JE
    J Nucl Cardiol; 2012 Jun; 19(3):448-57. PubMed ID: 22395779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence for the robustness of regadenoson stress myocardial perfusion SPECT: its predictive value for cardiac events in chronic renal failure.
    Caobelli F; Bengel FM
    Eur Heart J Cardiovasc Imaging; 2014 Aug; 15(8):941-2. PubMed ID: 24714138
    [No Abstract]   [Full Text] [Related]  

  • 14. The Feasibility, Tolerability, Safety, and Accuracy of Low-radiation Dynamic Computed Tomography Myocardial Perfusion Imaging With Regadenoson Compared With Single-photon Emission Computed Tomography.
    van Assen M; Duguay TM; Litwin SE; Bayer RR; Nance JW; Suranyi P; De Cecco CN; Varga-Szemes A; Jacobs BE; Johnson AA; Tesche C; Schoepf UJ
    J Thorac Imaging; 2021 Nov; 36(6):345-352. PubMed ID: 32205821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction.
    Bhatti S; Hakeem A; Dhanalakota S; Palani G; Husain Z; Jacobsen G; Ananthasubramaniam K
    Eur Heart J Cardiovasc Imaging; 2014 Aug; 15(8):933-40. PubMed ID: 24699324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Gomez J; Fughhi I; Campagnoli T; Ali A; Doukky R
    J Nucl Cardiol; 2017 Oct; 24(5):1666-1671. PubMed ID: 27251142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.
    AlJaroudi W; Campagnoli T; Fughhi I; Wassouf M; Ali A; Doukky R
    J Nucl Cardiol; 2016 Jun; 23(3):560-9. PubMed ID: 26293358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison.
    Cury RC; Kitt TM; Feaheny K; Akin J; George RT
    J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asystole following Regadenoson administration: Review of literature, risk factors and management.
    Asif T; Lee Chuy K; Malhotra S
    J Nucl Cardiol; 2021 Oct; 28(5):2046-2055. PubMed ID: 32462632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.